Daily Stock Opinions and Ratings

Opinions

John Zechner Novelion NVLN-T WEAK BUY Mar 09, 2005

Sold his holdings last year and hasn't come back to it yet, but is watching closely. Visudyne now has growing competition. Didn't like the Attrix acquisition and not sure if they will get any growth from it. Has good cash position, assets and core product.

John Zechner

Unlock Rating

$15.360

Stock price when the opinion was issued

biotechnology pharmaceutical

It's the ideal tool to help you make quicker, more informed decisions for managing and tracking your investments.

Get Signals Create your Watchlist

You might be interested:

DON'T BUY

This is bottom fishing, bargain hunting on a stock that is below the 200 day moving average. This stock is really base building. The stock is not participating in this bull market, so will possibly sit out the next bear market and you may have to wait for the next bull market which could be 2 years away.

SELL

Their treatment of macular degeneration only treats the latter stage while the competition is going after the initial stage. This company is like a one trick pony. Major competition is coming in.

DON'T BUY

A one trick pony. Visudine is great, but they haven't really gone beyond this. Getting new competition.

WAIT

Likes the company from the standpoint of a product. Thinks they are still way ahead of the competitors, particularily in the eye treatment area. Have expanded their product base which is not bad. Market has been unmerciful to this stock. Hopefully it has hit a bottom, but would wait to see if the stock can work its way through.

DON'T BUY

Looks cheap at 10 X earnings. Have a drug that is photo-activated, but competitors have come which has pulled the stock down. Bought a company that had an acne cream, but because of labeling problems, it's another year or two away.

DON'T BUY

The drug companys are due for a slow turn around. Had a lot of problems with the FDA. Lots of competition going to happen.

SELL

The biggest threat to any business is a competing technology or product. That's what the market thinks is happening here.

DON'T BUY

Has been a very disappointing stock. Had problems with its major drug because of competition. The problem with the Canadian drug sector is that it tends to be one or two drug dependent.

SELL

The future isn't bright. Losing market share with their main product. Suggests tax loss selling.

BUY ON WEAKNESS

(Market Call Minute.) Could see it as a Buy but would like it at a cheaper price.

Stockchase, in its reporting on what has been discussed by individuals on business television programs (in particular Business News Network), neither recommends nor promotes any investment strategies.

We paraphrase the experts by hand, we watch the shows and write down what we understood from the experts’ comments. We are human and can make mistakes, help us fix any errors. If you see something that you know is not right or if there is a problem with the site, feel free to email us at : hello@stockchase.com.

John Zechner Novelion NVLN-T WEAK BUY Mar 09, 2005

You might be interested:

Novelion(NVLN-T)

Novelion(NVLN-T)

Novelion(NVLN-T)

Novelion(NVLN-T)

Novelion(NVLN-T)

Novelion(NVLN-T)

Novelion(NVLN-T)

Novelion(NVLN-T)

Novelion(NVLN-T)

Novelion(NVLN-T)

Latest Buy Signals

Today's Top Picks

Popular Articles

Latest Sell Signals

Most Recent Experts

Eric Nuttall

The Panic-Proof Portfolio (Stockchase Research)

David Burrows

Larry Berman CFA, CMT, CTA

Stockchase Insights